148 related articles for article (PubMed ID: 33984552)
1. Osteoporosis medication is associated with mortality risk reduction among adults with epilepsy: An observational study.
Whitney DG
Bone; 2021 Sep; 150():116003. PubMed ID: 33984552
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of osteoporosis medication on site-specific fracture-risk attenuation among adults with epilepsy.
Whitney DG
Epilepsia; 2020 Nov; 61(11):2583-2592. PubMed ID: 33090479
[TBL] [Abstract][Full Text] [Related]
3. The effect of age when initiating anti-seizure medication therapy on fragility fracture risk for children with epilepsy.
Whitney DG; Kalia V; Rajapakse CS; Fedak Romanowski EM; Caird MS; Hurvitz EA; Jepsen KJ
Bone; 2021 Aug; 149():115996. PubMed ID: 33962082
[TBL] [Abstract][Full Text] [Related]
4. Effect of levetiracetam and oxcarbazepine on 4-year fragility fracture risk among prepubertal and pubertal children with epilepsy.
Whitney DG; Caird MS; Hurvitz EA; Rajapakse CS; Fedak Romanowski EM
Epilepsia; 2021 Sep; 62(9):2180-2189. PubMed ID: 34250606
[TBL] [Abstract][Full Text] [Related]
5. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
[TBL] [Abstract][Full Text] [Related]
6. The mortality burden attributable to nontrauma fracture for privately insured adults with epilepsy.
Whitney DG; Bell S; McNamara NA; Hurvitz EA
Epilepsia; 2020 Apr; 61(4):714-724. PubMed ID: 32108937
[TBL] [Abstract][Full Text] [Related]
7. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
[TBL] [Abstract][Full Text] [Related]
8. Risk for respiratory and cardiovascular disease and mortality after non-trauma fracture and the mediating effects of respiratory and cardiovascular disease on mortality risk among adults with epilepsy.
Whitney DG; Kannikeswaran S; Whibley D
Epilepsy Res; 2020 Oct; 166():106411. PubMed ID: 32679488
[TBL] [Abstract][Full Text] [Related]
9. Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland.
Walsh ME; Fahey T; Moriarty F
Arch Osteoporos; 2021 Apr; 16(1):71. PubMed ID: 33864529
[TBL] [Abstract][Full Text] [Related]
10. Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study.
Hung CC; Wang CY; Fu SH; Yang RS; Hsiao FY
Arch Osteoporos; 2018 Oct; 13(1):107. PubMed ID: 30306268
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan.
Fu SH; Wang CY; Yang RS; Wu FL; Hsiao FY
J Bone Joint Surg Am; 2017 Jun; 99(11):938-946. PubMed ID: 28590379
[TBL] [Abstract][Full Text] [Related]
12. Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study.
Yu SF; Cheng JS; Chen YC; Chen JF; Hsu CY; Lai HM; Ko CH; Chiu WC; Su YJ; Cheng TT
BMC Geriatr; 2019 Oct; 19(1):290. PubMed ID: 31660863
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate use after clinical fracture and risk of new fracture.
Bergman J; Nordström A; Nordström P
Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
[TBL] [Abstract][Full Text] [Related]
15. Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease.
Kao CC; Wu PC; Chuang MT; Yeh SC; Lin YC; Chen HH; Fang TC; Chang WC; Wu MS; Chang TH
Postgrad Med J; 2023 May; 99(1170):340-349. PubMed ID: 37227976
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Osteoporosis Medication on Risk Attenuation of Non-Trauma Fracture Among Adults with Cerebral Palsy: A Propensity Score-Matched Observational Study.
Whitney DG; Hurvitz EA; Caird MS
Clin Epidemiol; 2021; 13():91-102. PubMed ID: 33603490
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and mortality: confounding in observational studies?
Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
[TBL] [Abstract][Full Text] [Related]
18. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
19. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
20. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
